Literature DB >> 18056352

Transduction of phosphatase and tensin homolog deleted on chromosome 10 into eosinophils attenuates survival, chemotaxis, and airway inflammation.

Tetsuya Adachi1, Satoko Hanaka, Tomoko Masuda, Hisanao Yoshihara, Hiroyuki Nagase, Ken Ohta.   

Abstract

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is part of a complex signaling system that affects a variety of important cell functions. PTEN antagonizes the action of PI3K by dephosphorylating the signaling lipid phosphatidylinositol 3,4,5-triphosphate. In the present study, we used a TAT fusion protein transduction system to elucidate the role of PTEN in eosinophils and airway inflammation. A small region of the HIV TAT protein (YGRKKRRQRRR), a protein transduction domain known to enter mammalian cells efficiently, was fused to the N terminus of PTEN. Flow cytometric analysis of annexin V- and propidium iodide-stained cells was used to assess eosinophil survival. A chemotaxis assay was performed using a Boyden chamber. Cell analysis in bronchoalveolar lavage fluid and histological examinations were performed using OVA-challenged A/J mice. We found that TAT-PTEN was successfully internalized into eosinophils and functioned as a phosphatase in situ. TAT-PTEN, but not a TAT-GFP control protein, blocked the ability of IL-5 to prevent the apoptosis of eosinophils from allergic subjects. The eotaxin-induced eosinophil chemotaxis was inhibited by TAT-PTEN in a dose-dependent manner. Intranasal pretreatment with TAT-PTEN, but not TAT-GFP, significantly inhibited the OVA-induced eosinophil infiltration in bronchoalveolar lavage fluid. Histological examination of the lung, including H&E and Alcian blue/periodic acid-Schiff staining, revealed that TAT-PTEN, but not TAT-GFP, abrogated eosinophilic inflammation and mucus production. Our results suggest that PTEN negatively regulates eosinophil survival, chemotaxis, and allergic inflammation. The pharmacological targeting of PTEN may constitute a new strategy for the treatment of eosinophilic disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056352     DOI: 10.4049/jimmunol.179.12.8105

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells.

Authors:  M R Moniri; L-J Dai; G L Warnock
Journal:  Cancer Gene Ther       Date:  2014-01-03       Impact factor: 5.987

2.  Loss-of-function of inositol polyphosphate-4-phosphatase reversibly increases the severity of allergic airway inflammation.

Authors:  Jyotirmoi Aich; Ulaganathan Mabalirajan; Tanveer Ahmad; Anurag Agrawal; Balaram Ghosh
Journal:  Nat Commun       Date:  2012-06-06       Impact factor: 14.919

3.  Histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced histamine release is enhanced with SHIP-1 knockdown in cultured human mast cell and basophil models.

Authors:  Jacqueline M Langdon; John T Schroeder; Becky M Vonakis; Anja P Bieneman; Kristin Chichester; Susan M Macdonald
Journal:  J Leukoc Biol       Date:  2008-07-14       Impact factor: 4.962

4.  Increased prevalence of eosinophilic gastrointestinal disorders in pediatric PTEN hamartoma tumor syndromes.

Authors:  Carol J Henderson; Joanne Ngeow; Margaret H Collins; Lisa J Martin; Philip E Putnam; Juan P Abonia; Keith Marsolo; Charis Eng; Marc E Rothenberg
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-05       Impact factor: 2.839

Review 5.  An understanding of the genetic basis of asthma.

Authors:  Mahdi Bijanzadeh; Padukudru A Mahesh; Nallur B Ramachandra
Journal:  Indian J Med Res       Date:  2011-08       Impact factor: 2.375

6.  miRNA-221-3p Enhances the Secretion of Interleukin-4 in Mast Cells through the Phosphatase and Tensin Homolog/p38/Nuclear Factor-kappaB Pathway.

Authors:  Yao Zhou; Qianyuan Yang; Hong Xu; Jiamin Zhang; Huan Deng; Haiyan Gao; Jin Yang; Deyu Zhao; Feng Liu
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.